Implementation and Evaluation of a Rare Disease Algorithm to Identify Persons at Risk of Gaucher Disease Using Data From Electronic Health Records (EHRs) in the United States (Project Searchlight)

About the trial

Sponsor

Sanofi

Tested

Investigational procedure (procedure)

Dates

Started 2024-04-02; completion 2024-08-26

Results posted

Not yet

This is a three-phase study comprising both retrospective and prospective components, as follows: Phase I: Deployment of Rare Disease Algorithm: A diagnostic screening algorithm was developed using advanced analytical methods to identify patients who have an increased likelihood of having Gaucher disease. This tool will be applied to a health system's electronic health records (EHR). The top 50 active patients per healthcare system will be identified as "highly ranked by the RDA" and moved to Phase II. As three to four healthcare systems are expected to participate in this study, between 150 to 200 persons are expected to be identified and included in Phase II. Phase II: Retrospective rev…

From ClinicalTrials.gov, last updated 2024-11-19. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Sanofi US Services Inc. reported $369,852 in research payments for this study in 2025 (16 payments).

Products named: Cerdelga

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.